Literature DB >> 2039207

Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice.

S Pecquet1, E Chachaty, C Tancrède, A Andremont.   

Abstract

The ecological impact of roxithromycin given orally at 300 mg/day on the intestinal floras in six human volunteers was studied. The resulting fecal concentrations of active roxithromycin were in the range of 100 to 200 micrograms/g of feces. Consecutive modifications in the composition of the fecal floras were limited to a decrease in counts of total members of the family Enterobacteriaceae. The rest of the intestinal floras, including the predominant anaerobic floras, changed little. No overgrowth of Pseudomonas aeruginosa, staphylococci, fungi, or highly erythromycin-resistant strains of the family Enterobacteriaceae was observed. The strains of Enterobacteriaceae and of anaerobes isolated during treatment were not markedly more resistant to roxithromycin than those isolated before treatment started. Changes in intestinal resistance to colonization by exogenous microorganisms in gnotobiotic mice inoculated with human fecal flora were studied and were also found to be minimal. The impact of oral roxithromycin on the intestinal microbiota appears to be weaker than that previously observed with oral erythromycin, perhaps because the concentrations of roxithromycin in the feces were lower than those previously found for erythromycin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039207      PMCID: PMC245048          DOI: 10.1128/AAC.35.3.548

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  [Practical modifications concerning the determination of antibiotics in clinical practice].

Authors:  Y CHABBERT; H BOULINGRE
Journal:  Rev Fr Etud Clin Biol       Date:  1957-06

2.  Effect of oral ofloxacin on fecal bacteria in human volunteers.

Authors:  S Pecquet; A Andremont; C Tancrède
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

3.  Epidemiology of intestinal colonization by members of the family Enterobacteriaceae highly resistant to erythromycin in a hematology-oncology unit.

Authors:  A Andremont; H Sancho-Garnier; C Tancrede
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

4.  Isolation of anaerobic bacteria from human gingiva and mouse cecum by means of a simplified glove box procedure.

Authors:  A Arank; S A Syed; E B Kenney; R Freter
Journal:  Appl Microbiol       Date:  1969-04

5.  On the logarithmid transformation of intestinal bacterial counts.

Authors:  W R Best
Journal:  Am J Clin Nutr       Date:  1970-12       Impact factor: 7.045

Review 6.  Antimicrobial prophylaxis of travelers' diarrhea: a selected summary.

Authors:  R B Sack
Journal:  Rev Infect Dis       Date:  1986 May-Jun

7.  Plasmid-mediated susceptibility to intestinal microbial antagonisms in Escherichia coli.

Authors:  A Andremont; G Gerbaud; C Tancrède; P Courvalin
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

8.  Effect of erythromycin on microbial antagonisms: a study in gnotobiotic mice associated with a human fecal flora.

Authors:  A Andremont; P Raibaud; C Tancrède
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

9.  Reduction of the aerobic Gram negative bacterial flora of the gastro-intestinal tract and prevention of traveller's diarrhea using oral erythromycin.

Authors:  A Andremont; C Tancrede
Journal:  Ann Microbiol (Paris)       Date:  1981 Nov-Dec

10.  Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora.

Authors:  S Pecquet; A Andremont; C Tancrède
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

View more
  7 in total

1.  Roxithromycin inhibits nuclear factor kappaB signaling and endoplasmic reticulum stress in intestinal epithelial cells and ameliorates experimental colitis in mice.

Authors:  Younjeong Choi; Seong-Joon Koh; Hee Sook Lee; Ji Won Kim; Byeong Gwan Kim; Kook Lae Lee; Joo Sung Kim
Journal:  Exp Biol Med (Maywood)       Date:  2015-06-18

2.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

3.  Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota.

Authors:  Mamun-Ur Rashid; Staffan Rosenborg; Georgios Panagiotidis; Johan Holm; Karin Söderberg Löfdal; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

4.  In vitro activity of azithromycin against bacterial enteric pathogens.

Authors:  M E Gordillo; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

5.  Kinetics of Saccharomyces cerevisiae elimination from the intestines of human volunteers and effect of this yeast on resistance to microbial colonization in gnotobiotic mice.

Authors:  S Pecquet; D Guillaumin; C Tancrede; A Andremont
Journal:  Appl Environ Microbiol       Date:  1991-10       Impact factor: 4.792

Review 6.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 7.  Gut Microbiota, Antibiotic Therapy and Antimicrobial Resistance: A Narrative Review.

Authors:  Benoit Pilmis; Alban Le Monnier; Jean-Ralph Zahar
Journal:  Microorganisms       Date:  2020-02-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.